About Neon Therapeutics
Neon Therapeutics is a company based in Cambridge (United States) founded in 2015 was acquired by BioNTech in January 2020. Neon Therapeutics has raised $161 million across 3 funding rounds from investors including Fidelity Investments, BioNTech and ArrowMark Partners. The company has 306 employees as of December 31, 2022. Neon Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Cambridge, United States
- Employees 306 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neon Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$79.78 M (USD)-4as on Dec 31, 2019
-
EBITDA
-$81.14 M (USD)-3as on Dec 31, 2019
-
Total Equity Funding
$161 M (USD)
in 3 rounds
-
Latest Funding Round
$36 M (USD), Series B
Dec 13, 2017
-
Investors
Fidelity Investments
& 12 more
-
Employee Count
306
as on Dec 31, 2022
-
Acquired by
BioNTech
(Jan 16, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Neon Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Neon Therapeutics
Neon Therapeutics has successfully raised a total of $161M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $36 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neon Therapeutics
Neon Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, BioNTech and ArrowMark Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and holding company controlled by Len Blavatnik
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked |
Investor details for Neon Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neon Therapeutics
Investment portfolio details for Neon Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neon Therapeutics
Detailed financials for Neon Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neon Therapeutics Comparisons
Peer comparison for Neon Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neon Therapeutics
Neon Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Neon Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neon Therapeutics
Complete news archive for Neon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neon Therapeutics
Neon Therapeutics was founded in 2015.
Neon Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Neon Therapeutics is a funded company, having raised a total of $161M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Neon Therapeutics is 306.
Neon Therapeutics develops personalized vaccines and autologous T-cell therapies for cancer. It is based on research from the Dana Farber Cancer Institute, the Broad Institute and the Massachusetts General Hospital. The company has a proprietary platform for identifying targets through immune monitoring and epitope profiling. Their lead candidate, NEO-PV-01, is a personalized neoantigen vaccine for cancer that is being investigated for the treatment of melanoma, smoking associated NSCLC, and bladder cancer and is currently undergoing clinical development (Phase 1b trials) in combination with Opdivo. The company uses next-generation genomic sequencing, a proprietary computational pipeline (which identifies cancer mutations and determines which mutations are most likely to encode immunogenic neoantigens recognized on tumor cells) and an n1 manufacturing process to produce vaccines that specifically target individual patient tumors. In addition, Neon Therapeutics is also investigating targeted autologous T-cell therapies for other oncology investigations.
Neon Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Neon Therapeutics has 13 investors. Key investors include Fidelity Investments, BioNTech, ArrowMark Partners, Clal Biotechnology Industries, and Access Industries.